Pancreatic Cancer Research

ResearcherNara Medical UniversityActive in the last 2 years

Satoshi Yasuda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4323-7422; OpenAlex author ID A5035561731, A5122990263. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 6 papers · 2024: 6 papers · 2025: 2 papers · 2026: 1 paper

Papers 22

  1. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  2. Role of radiotherapy in surgical approaches to pancreatic cancer treatment: A narrative review. Co-author DOI 10.1002/ags3.70012↗
  3. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-025-02260-w↗
  4. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Co-author DOI 10.1002/ags3.12726↗
  5. Prognostic significance of creatine kinase in resected pancreatic cancer. First author DOI 10.1002/jhbp.12081↗
  6. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Co-author DOI 10.1016/j.pan.2024.07.013↗
  7. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.08.003↗
  8. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.10.007↗
  9. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer. First author DOI 10.1245/s10434-024-15985-4↗
  10. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12629↗
  11. Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12655↗
  12. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2023.06.001↗
  13. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic du… Co-author DOI 10.1016/j.pan.2023.10.014↗
  14. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. Co-author DOI 10.1097/xcs.0000000000000808↗
  15. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Co-author DOI 10.1186/s40792-023-01720-w↗
  16. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Co-author DOI 10.1007/s10147-022-02131-x↗
  17. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000395↗
  18. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Co-author DOI 10.1186/s13046-015-0144-7↗
  19. Clinical significance of CD155 expression in human pancreatic cancer. Co-author PMID 25862891↗
  20. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Co-author DOI 10.1007/s00534-012-0532-8↗
  21. PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis. Co-author DOI 10.1158/0008-5472.can-12-0328↗
  22. [Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report]. Co-author PMID 23267918↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 22 shared papers, 2012–2026 · strength 3.54
  2. Minako Nagai · 19 shared papers, 2015–2026 · strength 3.45
  3. Taichi Terai · 14 shared papers, 2022–2025 · strength 2.75
  4. Yuichiro Kohara · 13 shared papers, 2023–2025 · strength 2.60
  5. Kota Nakamura · 12 shared papers, 2023–2025 · strength 2.50
  6. Satoshi Nishiwada · 9 shared papers, 2015–2025 · strength 1.24
  7. Takahiro Akahori · 6 shared papers, 2012–2024 · strength 0.41
  8. Shoichi Kinoshita · 6 shared papers, 2012–2024 · strength 0.39
  9. Toshihiro Tanaka · 2 shared papers, 2013–2025 · strength 0.26
  10. Yoshiyuki Nakajima · 6 shared papers, 2012–2015 · strength 0.23
  11. Masayuki Otsuka · 1 shared paper, 2026 · strength 0.23
  12. Sohei Satoi · 1 shared paper, 2026 · strength 0.23
  13. Teiichi Sugiura · 1 shared paper, 2026 · strength 0.23
  14. Masafumi Imamura · 1 shared paper, 2026 · strength 0.23
  15. Hirofumi Akita · 1 shared paper, 2026 · strength 0.23
  16. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.23
  17. Kenichiro Uemura · 1 shared paper, 2026 · strength 0.23
  18. Riki Ninomiya · 1 shared paper, 2026 · strength 0.23
  19. Yuichi Nagakawa · 1 shared paper, 2026 · strength 0.23
  20. Yu Takahashi · 1 shared paper, 2026 · strength 0.23
  21. Michiaki Unno · 1 shared paper, 2026 · strength 0.23
  22. Satoshi Hirano · 1 shared paper, 2026 · strength 0.23
  23. Manabu Kawai · 1 shared paper, 2026 · strength 0.23
  24. Chiharu Uchiyama · 1 shared paper, 2024 · strength 0.21
  25. Ichiro Yamato · 5 shared papers, 2012–2015 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.